112.64
8.55 (8.21%)
| Penutupan Terdahulu | 104.09 |
| Buka | 104.16 |
| Jumlah Dagangan | 927,878 |
| Purata Dagangan (3B) | 1,007,367 |
| Modal Pasaran | 6,157,604,352 |
| Harga / Jualan (P/S) | 3.24 |
| Harga / Buku (P/B) | 4.73 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2026 |
| Margin Operasi (TTM) | -2,852.71% |
| EPS Cair (TTM) | -2.83 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 33.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.43% |
| Nisbah Semasa (MRQ) | 15.98 |
| Aliran Tunai Operasi (OCF TTM) | -90.87 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -52.44 M |
| Pulangan Atas Aset (ROA TTM) | -20.04% |
| Pulangan Atas Ekuiti (ROE TTM) | -28.73% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Dianthus Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | -0.33 |
|
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 7.87% |
| % Dimiliki oleh Institusi | 119.90% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Octagon Capital Advisors Lp | 31 Mar 2026 | 1,946,667 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |